1 |
2% sodium chondroitin sulfate |
Chondroitin sulfate |
[1] D00080 D00080 💬 |
- |
- |
226 [1] 226 💬 |
2 |
5% lidocaine/5 mg/ml 0.02% estradiol compound cream |
Estradiol |
[11] D00105 D00105, D00358 D00358, D01413 D01413, D01617 D01617, D01953 D01953, D02086 D02086, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D08127 D08127 💬 |
ESR1 [7] ESR1, ESR2, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [12] Adrenergic signaling in cardiomyocytes, Breast cancer, Dopaminergic synapse, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Taste transduction, Thyroid hormone signaling pathway |
226 [1] 226 💬 |
3 |
Adalimumab |
Adalimumab |
[1] D02597 D02597 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
019 [16] 19, 37, 40, 41, 46, 56, 84, 96, 97, 151, 160, 164, 222, 226, 269, 271 💬 |
4 |
Agn 203818 |
- |
- |
- |
- |
226 [1] 226 💬 |
5 |
Alkalinized lidocaine-heparin |
Heparin |
[4] D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A [6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes [4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 [1] 226 💬 |
6 |
Amitriptyline |
Amitriptyline |
[2] D00809 D00809, D07448 D07448 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
078 [4] 78, 97, 226, 299 💬 |
7 |
Aqx-1125 |
AQX-1125 |
- |
- |
- |
226 [1] 226 💬 |
8 |
Aqx-1125 100 mg |
AQX-1125 |
- |
- |
- |
226 [1] 226 💬 |
9 |
Aqx-1125 200 mg |
AQX-1125 |
- |
- |
- |
226 [1] 226 💬 |
10 |
Asp3652 |
- |
- |
- |
- |
226 [1] 226 💬 |
11 |
Asp6294 |
- |
- |
- |
- |
226 [1] 226 💬 |
12 |
Bladder instillation with heparin/ lidocaine |
Heparin |
[4] D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A [6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes [4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 [1] 226 💬 |
13 |
Bladder instillation with triamcinolone acetonide |
Triamcinolone |
[5] D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
226 [1] 226 💬 |
14 |
Bladder instillation without triamcinolone acetonide |
Triamcinolone |
[5] D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
226 [1] 226 💬 |
15 |
Bladder instillations |
- |
- |
- |
- |
226 [1] 226 💬 |
16 |
Botox |
- |
- |
- |
- |
002 [6] 2 , 6 , 13, 51, 149, 226 💬 |
17 |
Botox 200u in normal saline |
- |
- |
- |
- |
226 [1] 226 💬 |
18 |
Botulinum toxin a |
Botulinum toxin type A |
[1] D00783 D00783 💬 |
SNAP25 [1] SNAP25 💬 |
Insulin secretion [2] Insulin secretion, Synaptic vesicle cycle |
013 [4] 13, 51, 149, 226 💬 |
19 |
Buckwheat |
Buckwheat |
- |
- |
- |
226 [1] 226 💬 |
20 |
Bupivacaine |
Bupivacaine |
[2] D01450 D01450, D07552 D07552 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
046 [8] 46, 51, 53, 70, 96, 168, 226, 298 💬 |
21 |
Cannabidiol |
Cannabidiol |
[1] D10915 D10915 💬 |
CNR1 [2] CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction [4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
006 [17] 6 , 8 , 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 226, 271 💬 |
22 |
Cannabidiol vaginal suppository |
Cannabidiol |
[1] D10915 D10915 💬 |
CNR1 [2] CNR1, CNR2 💬 |
Neuroactive ligand-receptor interaction [4] Neuroactive ligand-receptor interaction, Rap1 signaling pathway, Retrograde endocannabinoid signaling, Thermogenesis |
226 [1] 226 💬 |
23 |
Capsaicin |
Capsaicin |
[1] D00250 D00250 💬 |
TRPV1 [1] TRPV1 💬 |
Inflammatory mediator regulation of TRP channels [2] Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
002 [5] 2 , 6 , 19, 86, 226 💬 |
24 |
Certolizumab pegol |
Certolizumab pegol |
[1] D03441 D03441 💬 |
TNF [1] TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications [65] AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
037 [6] 37, 46, 96, 97, 226, 271 💬 |
25 |
Chondroitin sulfate |
Chondroitin sulfate |
[1] D00080 D00080 💬 |
- |
- |
096 [2] 96, 226 💬 |
26 |
Ciclosporin |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
026 [13] 26, 46, 49, 50, 53, 55, 60, 61, 97, 222, 226, 228, 269 💬 |
27 |
Ciklosporin |
- |
- |
- |
- |
226 [1] 226 💬 |
28 |
Combination product: hyperbaric oxygen therapy- |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
226 [1] 226 💬 |
29 |
Cyclosporine |
Cyclosporine |
[1] D00184 D00184 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
011 [35] 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 63, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 💬 |
30 |
Device: interferential current |
- |
- |
- |
- |
226 [1] 226 💬 |
31 |
Device: intermittent exposure to oxygen via oro-nasal mask |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
226 [1] 226 💬 |
32 |
Dexmedetomidine |
Dexmedetomidine |
[2] D00514 D00514, D01205 D01205 💬 |
ADRA2A [3] ADRA2A, ADRA2B, ADRA2C 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway |
002 [12] 2 , 4 , 6 , 21, 34, 46, 70, 113, 212, 215, 226, 280 💬 |
33 |
Dimethyl sulfoxide |
Dimethyl sulfoxide |
[1] D01043 D01043 💬 |
- |
- |
226 [1] 226 💬 |
34 |
Dmso |
Dimethyl sulfoxide |
[1] D01043 D01043 💬 |
- |
- |
226 [1] 226 💬 |
35 |
Dmso cocktail |
Dimethyl sulfoxide |
[1] D01043 D01043 💬 |
- |
- |
226 [1] 226 💬 |
36 |
Erb-041 |
- |
- |
- |
- |
046 [3] 46, 96, 226 💬 |
37 |
Estradiol |
Estradiol |
[8] D00105 D00105, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 [2] ESR1, ESR2 💬 |
Breast cancer [9] Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
013 [5] 13, 46, 49, 226, 299 💬 |
38 |
Fospropofol |
Fospropofol |
[1] D04257 D04257 💬 |
- |
- |
226 [1] 226 💬 |
39 |
Fospropofol (lusedra®) 10 |
Fospropofol |
[1] D04257 D04257 💬 |
- |
- |
226 [1] 226 💬 |
40 |
Fospropofol (lusedra®) 12 |
Fospropofol |
[1] D04257 D04257 💬 |
- |
- |
226 [1] 226 💬 |
41 |
Fospropofol (lusedra®) 6.5 |
Fospropofol |
[1] D04257 D04257 💬 |
- |
- |
226 [1] 226 💬 |
42 |
Fremanezumab |
Fremanezumab |
[1] D11055 D11055 💬 |
CALCA [1] CALCA 💬 |
Neuroactive ligand-receptor interaction [2] Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction |
124 [2] 124, 226 💬 |
43 |
Gefapixant |
Gefapixant |
[1] D11349 D11349 💬 |
P2RX3 [1] P2RX3 💬 |
Calcium signaling pathway [3] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction |
085 [2] 85, 226 💬 |
44 |
Glycine |
Glycine |
[1] D00011 D00011 💬 |
- |
- |
035 [5] 35, 60, 86, 226, 299 💬 |
45 |
Gralise |
- |
- |
- |
- |
097 [2] 97, 226 💬 |
46 |
Heparin |
Heparin |
[1] D07510 D07510 💬 |
SERPINC1 [1] SERPINC1 💬 |
Complement and coagulation cascades [1] Complement and coagulation cascades |
060 [11] 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 💬 |
47 |
Heparin & alkalinized lidocaine bladder instillation |
Heparin |
[4] D00358 D00358, D02086 D02086, D07510 D07510, D08127 D08127 💬 |
SCN1A [6] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SERPINC1 💬 |
Adrenergic signaling in cardiomyocytes [4] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Taste transduction |
226 [1] 226 💬 |
48 |
Hyaluronic acid |
Hyaluronic acid |
[1] D08043 D08043 💬 |
- |
- |
046 [5] 46, 53, 70, 226, 231 💬 |
49 |
Hyaluronic acid and chondroitin sulfate |
Chondroitin sulfate |
[2] D00080 D00080, D08043 D08043 💬 |
- |
- |
226 [1] 226 💬 |
50 |
Hyaluronic acid/chondroitin sulfate |
Chondroitin sulfate |
[2] D00080 D00080, D08043 D08043 💬 |
- |
- |
226 [1] 226 💬 |
51 |
Hydrogen |
Hydrogen |
- |
- |
- |
005 [7] 5 , 6 , 13, 17, 83, 97, 226 💬 |
52 |
Ic cocktail |
- |
- |
- |
- |
226 [1] 226 💬 |
53 |
Intravesical onabotulinumtoxina injection |
Botulinum toxin type A |
[1] D00783 D00783 💬 |
SNAP25 [1] SNAP25 💬 |
Insulin secretion [2] Insulin secretion, Synaptic vesicle cycle |
226 [1] 226 💬 |
54 |
Ipd® (japanese tradename) |
- |
- |
- |
- |
226 [1] 226 💬 |
55 |
Ipd® (suplatast tosilate) |
- |
- |
- |
- |
226 [1] 226 💬 |
56 |
Jnj-42160443 |
- |
- |
- |
- |
226 [1] 226 💬 |
57 |
Ketorolac |
Ketorolac |
[2] D00813 D00813, D08104 D08104 💬 |
PTGS1 [2] PTGS1, PTGS2 💬 |
Alzheimer disease [23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
070 [2] 70, 226 💬 |
58 |
Ketorolac tromethamine |
Ketorolac |
[3] D00396 D00396, D00813 D00813, D08104 D08104 💬 |
PTGS1 [2] PTGS1, PTGS2 💬 |
Alzheimer disease [23] Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
226 [1] 226 💬 |
59 |
Krp-116d |
- |
- |
- |
- |
226 [1] 226 💬 |
60 |
Lidocaine |
Lidocaine |
[3] D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
006 [10] 6 , 13, 34, 46, 51, 86, 168, 226, 231, 256 💬 |
61 |
Lidocaine releasing intravesical system - liris® |
Lidocaine |
[3] D00358 D00358, D02086 D02086, D08127 D08127 💬 |
SCN1A [5] SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes [3] Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
226 [1] 226 💬 |
62 |
Liposome encapsulated bont-a |
- |
- |
- |
- |
226 [1] 226 💬 |
63 |
Liposomes |
- |
- |
- |
- |
226 [1] 226 💬 |
64 |
Liris 400 mg |
- |
- |
- |
- |
226 [1] 226 💬 |
65 |
Liris low dose and liris high dose |
- |
- |
- |
- |
226 [1] 226 💬 |
66 |
Liris® |
- |
- |
- |
- |
226 [1] 226 💬 |
67 |
Liris® 400 mg |
- |
- |
- |
- |
226 [1] 226 💬 |
68 |
Low-dose naltrexone |
Naltrexone |
[2] D02095 D02095, D05113 D05113 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
69 |
Lp-08 20mg |
- |
- |
- |
- |
226 [1] 226 💬 |
70 |
Lp-08 80mg |
- |
- |
- |
- |
226 [1] 226 💬 |
71 |
Metoprolol |
Metoprolol |
[3] D00601 D00601, D02358 D02358, D05011 D05011 💬 |
ADRB1 [1] ADRB1 💬 |
Adrenergic signaling in cardiomyocytes [10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
017 [6] 17, 57, 58, 113, 193, 226 💬 |
72 |
Metoprolol tartrate oral tablet |
Metoprolol |
[3] D00601 D00601, D02358 D02358, D05011 D05011 💬 |
ADRB1 [1] ADRB1 💬 |
Adrenergic signaling in cardiomyocytes [10] Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
73 |
Mirabegron |
Mirabegron |
[1] D09535 D09535 💬 |
ADRB3 [1] ADRB3 💬 |
Calcium signaling pathway [7] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cGMP-PKG signaling pathway |
006 [3] 6 , 13, 226 💬 |
74 |
Mmf |
- |
- |
- |
- |
013 [13] 13, 35, 40, 49, 50, 51, 60, 65, 66, 222, 224, 226, 299 💬 |
75 |
Mn-001 |
- |
- |
- |
- |
226 [1] 226 💬 |
76 |
Mn-001 bid |
- |
- |
- |
- |
226 [1] 226 💬 |
77 |
Mr-mc-01 |
- |
- |
- |
- |
226 [1] 226 💬 |
78 |
Mycofenolate mofetil (mmf) |
- |
- |
- |
- |
226 [1] 226 💬 |
79 |
Mycophenolate |
Mycophenolic acid |
[1] D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [34] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬 |
80 |
Mycophenolate mofetil |
Mycophenolate mofetil |
[4] D00752 D00752, D05094 D05094, D05095 D05095, D05096 D05096 💬 |
IMPDH1 [2] IMPDH1, IMPDH2 💬 |
Drug metabolism - other enzymes [3] Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism |
002 [32] 2 , 11, 13, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬 |
81 |
Naloxone |
Naloxone |
[2] D01340 D01340, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [2] 6 , 226 💬 |
82 |
Naloxone hydrochloride |
Naloxone |
[2] D01340 D01340, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
83 |
Naltrexone |
Naltrexone |
[2] D02095 D02095, D05113 D05113 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [12] 6 , 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬 |
84 |
Normal saline |
- |
- |
- |
- |
006 [16] 6 , 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 276, 296, 299 💬 |
85 |
Normal saline instillation |
- |
- |
- |
- |
226 [1] 226 💬 |
86 |
Nortriptyline |
Nortriptyline |
[2] D00816 D00816, D08288 D08288 💬 |
SLC6A2 [2] SLC6A2, SLC6A4 💬 |
Serotonergic synapse [2] Serotonergic synapse, Synaptic vesicle cycle |
006 [2] 6 , 226 💬 |
87 |
Omalizumab |
Omalizumab |
[1] D05251 D05251 💬 |
FCER1A [1] FCER1A 💬 |
Asthma [4] Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 [7] 46, 53, 65, 98, 162, 226, 299 💬 |
88 |
Onabotulinum toxin a |
- |
- |
- |
- |
226 [1] 226 💬 |
89 |
Onabotulinumtoxin a |
- |
- |
- |
- |
051 [2] 51, 226 💬 |
90 |
Onabotulinumtoxina |
Botulinum toxin type A |
[1] D00783 D00783 💬 |
SNAP25 [1] SNAP25 💬 |
Insulin secretion [2] Insulin secretion, Synaptic vesicle cycle |
006 [3] 6 , 13, 226 💬 |
91 |
Other: hyperbaric oxygen therapy |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
097 [2] 97, 226 💬 |
92 |
Other: inactive drug |
- |
- |
- |
- |
226 [1] 226 💬 |
93 |
Other: normal saline |
- |
- |
- |
- |
013 [4] 13, 222, 226, 280 💬 |
94 |
Other: saline as a nasal spray |
- |
- |
- |
- |
226 [1] 226 💬 |
95 |
Oxn 10/5 mg pr |
- |
- |
- |
- |
226 [1] 226 💬 |
96 |
Oxn 20/10 mg pr |
- |
- |
- |
- |
226 [1] 226 💬 |
97 |
Oxn 5/2.5 mg pr |
- |
- |
- |
- |
226 [1] 226 💬 |
98 |
Oxycodone |
Oxycodone |
[3] D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [7] 6 , 13, 46, 70, 226, 231, 298 💬 |
99 |
Oxycodone hydrochloride |
Oxycodone |
[3] D03783 D03783, D05312 D05312, D05462 D05462 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
006 [4] 6 , 70, 226, 298 💬 |
100 |
Oxycodone naloxone prolonged release tablets |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
101 |
Oxycodone/naloxone prolonged release t |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
102 |
Oxycodone/naloxone prolonged release tablets 10/5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
103 |
Oxycodone/naloxone prolonged release tablets 20/10 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
104 |
Oxycodone/naloxone prolonged release tablets 5/2.5 mg |
Naloxone |
[5] D01340 D01340, D03783 D03783, D05312 D05312, D05462 D05462, D08249 D08249 💬 |
OPRD1 [3] OPRD1, OPRK1, OPRM1 💬 |
Estrogen signaling pathway [5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
105 |
Oxygen |
Oxygen |
[1] D00003 D00003 💬 |
- |
- |
006 [18] 6 , 13, 19, 46, 49, 70, 84, 85, 86, 88, 90, 96, 97, 193, 226, 294, 299, 330 💬 |
106 |
Oxytocin |
Oxytocin |
[1] D00089 D00089 💬 |
OXTR [1] OXTR 💬 |
Calcium signaling pathway [4] Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway |
006 [5] 6 , 127, 193, 206, 226 💬 |
107 |
Pd 0299685 |
- |
- |
- |
- |
226 [1] 226 💬 |
108 |
Pd 0299685 at 15mg bid |
- |
- |
- |
- |
226 [1] 226 💬 |
109 |
Pd 0299685 at 30mg bid |
- |
- |
- |
- |
226 [1] 226 💬 |
110 |
Pd-0299685 |
PD-0299685 |
- |
- |
- |
226 [1] 226 💬 |
111 |
Pentosan polysulfate |
Pentosan polysulfate |
[1] D05428 D05428 💬 |
- |
- |
019 [3] 19, 26, 226 💬 |
112 |
Pentosan polysulfate sodium 100 mg |
Pentosan polysulfate |
[1] D05428 D05428 💬 |
- |
- |
226 [1] 226 💬 |
113 |
Pf-04383119 |
- |
- |
- |
- |
226 [1] 226 💬 |
114 |
Placebo |
- |
- |
- |
- |
003 [26] 3 , 5 , 6 , 13, 14, 37, 40, 46, 49, 50, 51, 63, 66, 67, 79, 85, 86, 88, 96, 97, 140, 144, 149, 226, 271, 276 💬 |
115 |
Platelet enriched plasma |
- |
- |
- |
- |
226 [1] 226 💬 |
116 |
Platelet-rich plasma |
- |
- |
- |
- |
226 [1] 226 💬 |
117 |
Procedure: injections on posterior bladder wall excluding the trigone |
- |
- |
- |
- |
226 [1] 226 💬 |
118 |
Procedure: injections upper aspect of trigone of urinary bladder |
- |
- |
- |
- |
226 [1] 226 💬 |
119 |
Procedure: pelvic floor physical therapy |
- |
- |
- |
- |
226 [1] 226 💬 |
120 |
Procedure: sham cystoscopy procedure |
- |
- |
- |
- |
226 [1] 226 💬 |
121 |
Procedure: urodynamic study |
- |
- |
- |
- |
226 [1] 226 💬 |
122 |
Prograf |
- |
- |
- |
- |
060 [3] 60, 222, 226 💬 |
123 |
Propiverine |
Propiverine |
[1] D08441 D08441 💬 |
CACNA1C [9] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes [42] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
124 |
Propiverine hydrochloride |
Propiverine |
[1] D08441 D08441 💬 |
CACNA1C [9] CACNA1C, CACNA1D, CACNA1F, CACNA1S, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Adrenergic signaling in cardiomyocytes [42] Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Regulation of actin cytoskeleton, Renin secretion, Retrograde endocannabinoid signaling, Salivary secretion, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
226 [1] 226 💬 |
125 |
Rimso 50 |
- |
- |
- |
- |
226 [1] 226 💬 |
126 |
Rn624, ri624 |
- |
- |
- |
- |
226 [1] 226 💬 |
127 |
Sandimmun |
- |
- |
- |
- |
097 [2] 97, 226 💬 |
128 |
Sandimmun neoral |
- |
- |
- |
- |
060 [3] 60, 97, 226 💬 |
129 |
Si-722 |
- |
- |
- |
- |
226 [1] 226 💬 |
130 |
Sildenafil |
Sildenafil |
[2] D02229 D02229, D08514 D08514 💬 |
PDE5A [1] PDE5A 💬 |
Metabolic pathways [3] Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway |
006 [17] 6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬 |
131 |
Sulfate |
Sulfate ion |
- |
- |
- |
002 [25] 2 , 6 , 11, 13, 26, 28, 34, 36, 46, 49, 53, 60, 64, 66, 79, 85, 86, 96, 111, 222, 226, 265, 296, 297, 299 💬 |
132 |
Suplatast tosilate |
- |
- |
- |
- |
226 [1] 226 💬 |
133 |
Tacrolimus |
Tacrolimus |
[2] D00107 D00107, D08556 D08556 💬 |
PPP3CA [5] PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 |
Alzheimer disease [32] Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
002 [32] 2 , 6 , 11, 13, 36, 46, 49, 50, 51, 53, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 299 💬 |
134 |
Tanezumab |
Tanezumab |
[1] D09387 D09387 💬 |
NGF [1] NGF 💬 |
Apoptosis [9] Apoptosis, Calcium signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway |
226 [2] 226, 298 💬 |
135 |
Targinact 10 mg/5 mg prolonged-release tablets |
- |
- |
- |
- |
006 [2] 6 , 226 💬 |
136 |
Targinact 20mg/10 mg prolonged-release tablets |
- |
- |
- |
- |
226 [1] 226 💬 |
137 |
Targinact 5mg/2.5 mg prolonged-release tablets |
- |
- |
- |
- |
226 [1] 226 💬 |
138 |
Tramadol |
Tramadol |
[2] D01355 D01355, D08623 D08623 💬 |
OPRM1 [1] OPRM1 💬 |
Estrogen signaling pathway [3] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction |
046 [5] 46, 70, 78, 226, 271 💬 |
139 |
Triamcinolone |
Triamcinolone |
[5] D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 [1] NR3C1 💬 |
Neuroactive ligand-receptor interaction [1] Neuroactive ligand-receptor interaction |
035 [8] 35, 46, 56, 70, 90, 96, 226, 298 💬 |
140 |
Tromethamine |
Tromethamine |
[1] D00396 D00396 💬 |
- |
- |
226 [1] 226 💬 |
141 |
Tti-1612 |
- |
- |
- |
- |
226 [1] 226 💬 |
142 |
Urg101 |
- |
- |
- |
- |
226 [1] 226 💬 |
143 |
Water |
Water |
[1] D00001 D00001 💬 |
- |
- |
002 [22] 2 , 5 , 6 , 13, 17, 19, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 💬 |
144 |
Ym672 |
- |
- |
- |
- |
226 [1] 226 💬 |
145 |
Ym672 (ipd®) |
- |
- |
- |
- |
226 [1] 226 💬 |